GLP-1 is an incretin hormone with glucose regulatory capacities that lead to glucose-dependent insulin secretion. 2 This has made the GLP-1 system an attractive target for the treatment of diabetes. 3 Importantly, treatment with GLP-1 receptor agonists has been shown to reduce cardiovascular mortality in high-risk patients with diabetes. 3 The cardioprotective effects of GLP-1 are incompletely understood and include infarct-sparing capacities in response to myocardial infarction. 4 Secretion of GLP-1 occurs in response to food and inflammatory stimuli. 5 High-circulating GLP-1 concentrations are present in critically ill patients with sepsis and correlate with parameters of inflammation. 6 Inflammation-dependent GLP-1 secretion proved to be a relevant modulator of glucose metabolism in response to endotoxin, while the cardiac consequences of GLP-1 secretion under these conditions remain unexplored. 6, 7 Thus, we sought to investigate the role of endogenous GLP-1 in response to acute myocardial infarction and to characterize its functional relevance for cardiac contractility and mitochondrial respiration. All procedures were approved by the ethical committee of UKAachen.
| MATERIAL AND METHODS

| Patients
GLP
| Animal studies
All experiments were approved by the government of NordrheinWestfalen (NRW, Germany). Myocardial infarction was induced by permanent LAD ligation using Ketamin 100 mg/kg/Xylazin 10 mg/kg anaesthesia in 6-week-old male C57BL/6J mice or in GLP-1 receptor KO mice (kind gift of Dan Drucker, University of Toronto). 8 Mice were pretreated with the DPP4 inhibitor linagliptin (3 mg/kg via oral gavage in a volume of 100ul/25 g body weight for 2 days) and/or Exendin-9
(100 nmol/kg), GLP-1 (7-36) (100 nmol/kg) or GLP-1 (9-36) (100 nmol/kg), all in a volume of 100 μL/25 g body weight by intraperitoneal injection for 1 day prior to LAD ligation in comparison to vehicle. The last drug application was performed 1 hour before surgery. Methodology of the surgical procedure, and serum and tissue analysis, in addition to mitochondrial respiratory measurements and statistical analyses, are presented online in Supporting Information (Appendix S1).
| RESULTS
The relevance of the endogenous GLP-1 system during acute myocardial infarction was suggested by the increased total GLP-1 concentrations found in patients presenting with ST-elevation myocardial infarction ( Figure 1A ), which were characterized by myocardial damage, with elevation of troponin and CK levels and an inflammatory reaction as indicated by increased IL6 concentrations and leukocytosis ( Figure 1A ,B and Table S1 ). Significant correlation was found between total GLP-1 and IL6 plasma concentrations (Spearman r = 0.44; P < 0.01) but with none of the other clinical parameters.
As inflammatory stimuli are known to increase GLP-1 secretion in mice, 6 we next examined whether the inflammatory reaction present during myocardial infarction is sufficient to increase circulating GLP-1.
Permanent LAD ligation served as a strong inflammatory stimulus in Cardiac contractility as assessed by a Millar catheter 3 and 6 hours post LAD ligation, with or without linagliptin (3 mg/kg) (Sham, n = 4; MI, n = 5; MI + Linagl., n = 4 at 3-hour timepoint and Sham, n = 6; MI, n = 12; MI + Linagl., n = 13 at 6-hour timepoint) (K) or GLP-1 (100 nmol) (Sham, n = 4; MI, n = 5; MI + GLP-1, n = 7 at 3-hour timepoint and Sham, n = 6; MI, n = 12; MI + GLP-1, n = 11 at 6-hour timepoint). (L) Treatment compared to SHAM procedure before and after dobutamine stress (2-way ANOVA). Exendin-9 (100 nmol) (n = 9) impairs cardiac contractility 6 hours post LAD ligation (n = 10) (2-way ANOVA) (M) and abrogates linagliptin (3 mg/kg) (n = 7) dependent improvement of cardiac contractility (N) (MI, n = 12; MI + Linagl., n = 14) (2-way ANOVA). Linagliptin (3 mg/kg) (n = 9) does not increase cardiac contractility in GLP-1 receptor KO mice (n = 13) 6 hours post LAD ligation (O) (2-way ANOVA). The GLP-1 metabolite (9-36) (100 nmol) (n = 6) does not increase cardiac contractility 6 hours post LAD ligation (n = 5) (P) (2-way ANOVA). Data are presented as mean AE SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Abbreviation: MI, myocardial infarction (H) (I) FIGURE 2 Western blot analysis of non-infarcted heart tissue of linagliptin (n = 6) (3 mg/kg) (A) or exendin 9-(n = 4) (100 nmol) (B) treated mice 6 hours post LAD ligation. Linagliptin does not increase AMPK phosphorylation in GLP-1 receptor KO mice (n = 5/group) (C). Respiratory quotient of state 3 to state 2 of primary isolated mitochondria from non-infarcted heart tissue of mice treated with linagliptin (3 mg/kg) (n = 10) in comparison to control (n = 17) (ANOVA) (D and E) or GLP-1 (100 nmol) (n = 8) in comparison to control (n = 6) (F and G) 6 hours post LAD ligation. State 1 indicates respiration of mitochondria only; state 2 indicates respiration with substrate (pyruvate/malate); state 3 indicates maximal respiration after addition of ADP; state 4 indicates status after inhibition of ATP synthase by oligomycin. Linagliptin (3 mg/kg) (n = 7) does not increase mitochondrial respiratory quotient (state 3 to state 2) in GLP-1 receptor KO mice (control; n = 8) (ANOVA) (H). The AMPK inhibitor dorsomorphine (10 mg/kg) (n = 6) abrogates linagliptin-dependent (3 mg/kg) (n = 6) improvement of cardiac contractility (I) (MI, n = 4; MI + Linagl., n = 4) (2-way ANOVA). Data are presented as mean AE SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Abbreviation: MI, myocardial infarction Pretreatment of mice with the AMPK inhibitor dorsomorphine (compound C) abrogated linagliptin-dependent augmentation of cardiac contractility 6 hours post LAD-ligation without affecting heart rate ( Figure 2I and Figure S1F ), suggesting AMPK dependency.
| DISCUSSION
In this study we found myocardial infarction to increase circulating GLP-1 concentrations both in patients and in a murine model of myocardial infarction. Time-dependent activation of the GLP-1 system led to augmentation of left ventricular contractility during myocardial infarction, which was attributable to activation of AMPK, with downstream induction of mitochondrial respiratory capacity in noninfarcted areas of the heart (illustrated in supplement Figure 2 ).
Myocardial infarction creates a massive inflammatory environment with the release of multiple inflammatory cytokines including
IL1β and IL6, which are known to increase secretion of GLP-1. 6, 7, 9, 10 Mechanistically, GLP-1 secretion has been attributed to an inflammatory cascade, which requires IL6 as an indispensable stimulus. 6, 11 We reveal here that myocardial infarction is a sufficient stimulus for the secretion of GLP-1, which most likely depends on a primary induction of IL6. This was suggested by significant correlation of IL6 and total GLP-1 plasma levels in the clinical cohort of our study.
Functionally, GLP-1 controls glucose metabolism by increasing glucose-dependent insulin secretion under inflammatory conditions, 6, 7 although activation of the GLP-1 system did not modulate glucose metabolism during myocardial infarction in our mouse model. This might be the consequence of the applied method of anaesthesia, with ketamine/xylazine providing a strong hyperglycaemic stimulus. activates Akt after ischaemia reperfusion injury as a relevant mechanism for myocardial salvage. 15 Further, GLP-1-dependent AKT activation was found to stimulate coronary endothelial cell proliferation under in vitro conditions. 21 These contradictory results might be the consequence of differential models (permanent LAD ligation vs ischaemia reperfusion injury), the location of the analysed tissue (non-infarcted vs infarcted area), the specific time point and the experimental system (in vivo vs in vitro). 5, 18 Additional investigations will be required to understand the relevance of endogenous GLP-1 secretion for patients with myocardial infarction. This might be reached by comparing the outcomes of patients with low vs high GLP-1 release after myocardial infarction. This approach, however, has also the potential to be misleading, given the inflammation-dependent regulation of GLP-1 secretion. High GLP-1 levels were subsequently found to imply a less favourable prognosis in critically ill patients and in patients with end-stage renal disease. 22 It will be of further interest to compare GLP-1 release in patients with and without diabetes after myocardial infarction, as diabetes has been reported to impair GLP-1 secretion in response to nutritional stimuli. 23 Finally, supplementation of GLP-1 might provide therapeutic benefit for patients with acute myocardial infarction. It seems possible, however, that the benefit remains restricted to those with low GLP-1 release despite high inflammatory activity, which will require further investigation.
In conclusion, we describe myocardial infarction as a stimulus for 
